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Abstract 
Objectives: To determine to what extent the Bonebridge improves clinical and health related 
quality of life outcomes in the New Zealand context.  
Methods: Preliminary results for 18 adults with conductive and mixed hearing loss, and single 
sided deafness who have undergone Bonebridge implantation are presented. Ear-specific 
audiometric thresholds were obtained pre implantation. Aided sound field audiometric thresholds 
were obtained post switch-on. Unaided and aided speech discrimination scores (SDSs) were 
obtained 4 weeks post switch-on. Health related quality of life information was assessed using 
patient reported outcome measures. An in-house developed questionnaire and the SSQ12-B were 
administered at 6 and 12 months post switch-on. The Health Utilities Index questionnaire was 
administered at 12 months or greater post switch-on.  
Results: The median intensity level at which participants obtained maximum SDS was 
significantly improved in the aided condition. The median half-peak level was significantly 
improved in the aided condition. The median SDS at 50 dB HL was significantly improved. SNR 
Loss score improved for 10 participants and an overall mean change score of 3.47 dB 
improvement in the aided condition was observed. HRQoL outcomes demonstrate high device 
usage, high ease of use and vocational performance, and perceived benefit in the speech, spatial 
and quality components of hearing.  
Conclusions: Overall improvements were seen in both Clinical and HRQoL Measures. This 
study proposes the Bonebridge as a viable solution for managing hearing loss in this population.  
Keywords: Bonebridge, clinical outcomes, quality of life, QoL, health related quality of life, 
HRQoL,  
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Bonebridge Health Related Quality of Life and Clinical Outcomes in New Zealand 
Introduction 
Hearing loss 
Hearing loss occurs when there is reduced or absent auditory input to the brain. It can be 
divided into two main subcategories. They are conductive hearing loss, and sensorineural hearing 
loss. If these occur simultaneously, it is called a mixed hearing loss (American Speech Language 
Hearing Association, 2019). 
Sensorineural hearing loss. 
Sensorineural hearing loss (SNHL) describes hearing loss that originates at the inner ear, 
i.e. the cochlear, or the auditory nerve. Normally it cannot be treated medically and is therefore 
permanent (American Speech Language Hearing Association, 2019). The causes of SNHL 
include genetic factors, infectious diseases, noise exposure, age, and other pathological 
processes. It can affect one or both ears and can be congenital or acquired. Hearing loss that 
occurs in one ear only is called unilateral hearing loss. If a unilateral SNHL is un-aidable, it is 
often called single sided deafness (SSD). 
Conductive hearing loss. 
Conductive hearing loss (CHL) describes hearing loss that originates at the middle or 
outer ear. It can be congenital or acquired. The middle ear structures are important for the 
transmission of acoustic energy from the external auditory meatus to the oval window of the 
cochlea and are responsible for correcting the impedance mismatch between the outer ear and 
inner ear (Zwislocki, 1962). If there is a blockage or pathological process that interferes with 
either the outer ear or the middle ear, the result may be a CHL. CHL, unlike SNHL, can 
BONEBRIDGE HRQOL AND CLINICAL OUTCOMES 14 
sometimes be medically treated. Some causes include congenital defects, middle or outer ear 
infections, trauma, and ossification of the middle ear bones. 
Prevalence 
Statistics New Zealand | Tatauranga Aotearoa (2013) state that hearing loss affects 9% of 
the population of New Zealand based on a 2013 disability survey. Further, the percentage of New 
Zealanders affected by hearing loss is projected to increase (Exeter, Wu, Lee, & Searchfield, 
2015). In the United States, Goman and Lin (2016) state that hearing loss effects 23% of 
Americans that are 12 years of age or older. From a global perspective, the World Health 
Organisation (2018) estimates that the global prevalence of hearing loss is 6.1%.  
Impact of hearing loss 
Psycho-social 
There are many consequences of hearing loss. Some negative consequences include 
difficulty with communication, reduced interpersonal interaction, social isolation, mental health 
and psychological complications, relationship problems and poorer health related quality of life 
(Manchaiah & Stephens, 2013). Hearing loss can also result in third-party disability meaning that 
the friends and family of persons with hearing loss can be affected (Scarinci, Worrall, & 
Hickson, 2009). 
Economic 
Hearing loss can also have economic consequences for the people affected. Persons with 
hearing loss have increased health care related costs compared to persons with normal hearing 
(Reed et al., 2019). Further, persons with hearing loss may experience a lower earning potential 
compared to their normal hearing peers (Emmett & Francis, 2015). Hearing loss also has an 
economic burden on society. A systematic review by Huddle et al. (2017) found that, in the 
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United States, there is wide variance in the estimates of the economic burden of hearing loss that 
results due to lost productivity but that it is likely billions of dollars annually. 
Health 
Persons affected by hearing loss may have an increased risk to their personal safety 
(Manchaiah & Stephens, 2013). There is also a higher rate of hospitalization and re-admission 
for persons with hearing loss (Reed et al., 2019), compared with persons with normal hearing. 
Ultimately, persons with hearing loss may experience lower health related outcomes than persons 
with normal hearing (Chia et al., 2007). 
Management of Hearing Loss 
Non-device Rehabilitation. 
Boothroyd (2007) describes the importance of not only improving auditory function 
using devices, but also the importance of instruction, counseling and perceptive training. He lists 
five categories regarding hearing loss that need to be addressed. They are anatomy and 
physiology, sensory function, activity, participation and Quality of Life (QoL). Where there is 
decreased cochlear integrity as a result of hair cell damage, anatomy and physiology cannot 
currently be addressed (Wan, Lovett, Warchol, & Stone, 2020). However sensory function can be 
addressed though devices and instruction. The activity, participation and QoL categories can be 
addressed through non-device interventions. Perceptual training, sometimes called auditory 
training, is an intervention that aims to enhances a person’s existing ability to perceive auditory 
and visual input (Boothroyd, 2007), and has been shown to be effective in clinical settings 
(Rubinstein & Boothroyd, 1987; Sweetow & Sabes, 2006). Counselling, as separate from 
instruction, is an intervention that aims to improve participation and QoL by discussing the 
impact of hearing loss and developing techniques to overcome it’s associated barriers 
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(Boothroyd, 2007), and has also been shown to be effective (Hawkins, 2005). Further, 
communication strategies form an important aspect of rehabilitation (Tye-Murray, 2018). 
Therefore, to achieve the best possible outcomes, it is important to address hearing loss with a 
range of non-device interventions including, instruction, counseling and perceptual training 
(Boothroyd, 2007),whether or not devices are used. 
Air conduction devices. 
Air conduction (AC) devices are well suited to providing amplification for SNHL. They 
are also able to provide amplification for CHL. Because this study is concerned with the 
Bonebridge, this section will be limited to the use of AC devices in the application of CHL, MHL 
and SSD, which are the intended applications for the Bonebridge (MED-EL, n.d.-b). 
There are some situations where using AC devices are not optimal or are not able to be 
used for CHL. AC hearing aids increase the risk of developing infection in the middle and outer 
ear (Kadhim, Colreavy, O'Donovan, & Blayney, 2004; Mylanus, van der Pouw, Snik, & Cremers, 
1998). Interventions that increase the risk of infection are not ideal because recurrent infections 
can damage inner ear structures which may lead to a decrease in cochlear reserve (Ricci et al., 
2010). AC hearing aids also need high levels of gain to overcome CHLs. This can increase the 
likelihood of feedback occurring. Further, very large conductive components can result in less 
optimal audiological outcomes. This is discussed in the bone conduction devices section. 
Regarding SSD, AC hearing aids have successfully been used for many years. The 
contralateral routing of signal (CROS) described by (Harford & Barry, 1965) is a technique to 
manage SSD. The aim of a CROS system is to eliminate the head shadow effect but acceptance 
is low in persons with normal hearing in the better ear (Harford & Dodds, 1966; Hol, Kunst, 
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Snik, & Cremers, 2010). The possibility of low acceptance highlights the importance of 
obtaining subjective outcomes when considering any device intervention. 
Bone conduction devices. 
Bone conduction devices stimulate the cochlear via the bone conduction mechanism 
which essentially bypasses the outer and middle ears. More precisely, the mechanism of bone 
conduction involves a complex assortment of skull vibrations (Stenfelt & Goode, 2005). The 
outer ear component involves vibration of the skull and cartilaginous portions of the external 
auditory canal and subsequent air conduction transmission (Steiger, 2015; Stenfelt & Goode, 
2005). The middle ear component involves vibrations of the ossicles, out of phase with the skull 
vibrations, and subsequent transmission of energy to the oval window (Steiger, 2015). Lastly, 
with the inner ear component, which itself involves numerous mechanisms including distortion 
of the cochlea, fluid inertia, and transmission though fluid within the skull (Stenfelt & Goode, 
2005; Tonndorf & Tonndorf, 1968). Soft tissue conduction was also described by de Jong et al. 
(2011). Ultimately, vibrations arrive at the cochlea via the inner, middle and outer ear 
mechanisms that cause displacement of cochlear fluid and initiate travelling waves in the basilar 
membrane (Steiger, 2015). 
Although AC devices can be used to manage CHL, at some degree of conductive 
component it will become more efficient to transmit acoustic energy via the bone conduction 
mechanism rather than the AC mechanism. Several studies have reported the benefit of bone 
conduction devices for managing CHLs in certain situations when compared to air conduction 
devices. Mylanus et al. (1998) suggested that if the air-bone gap was greater than 25 - 30 dB HL, 
that a bone conduction device will provide better audiological outcomes when compared to 
analogue behind-the-ear (BTE) AC hearing aids. Advances in AC hearing aid technology have 
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meant that BTEs can now be used to adequately manage CHLs with larger conductive 
components than before. A more recent study by de Wolf, Hendrix, Cremers, and Snik (2011) 
suggested that the crossover point at which a bone conduction device will produce better 
audiological outcomes is an air-bone gap of 35 dB HL or greater. In addition to managing CHLs 
and MHLs, they can also be used to manage SSD by functioning as a transcranial CROS system 
(Fowler, 1960; Welling et al., 1991). 
In some situations, bone conduction devices may provide additional advantages. Bone 
conduction devices do not occlude the ear canal which may be useful in a chronically 
discharging ear. Additionally, conditions such as aural atresia may preclude the use of air 
conduction devices all together, making bone conduction devices particularly useful. In some 
cases, bone-conduction devices may be the only viable option. A potential disadvantage of bone 
conduction devices, particularly surgically fitted ones, is the costs associated with surgery 
(Sardiwalla, Jufas, & Morris, 2017) which are not present in AC devices. 
Active versus Passive. 
Bone conduction devices can be classified as either passive or active. These terms may 
also be referred to as skin drive or direct drive respectively. Passive bone conduction systems 
have an external transducer that is in contact with the skin. The acoustic signal passes through 
the skin and tissue to the bone. The acoustic signal then stimulates the cochlea via the bone 
conduction mechanisms as described above. With active bone conduction systems, the transducer 
directly stimulates the bone. The acoustic signal then stimulates the cochlea via the bone 
conduction mechanisms. 
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Transcutaneous vs percutaneous. 
These terms describe the way in which a signal, either acoustic or digital, is passed 
through the skin. A percutaneous system uses a hard connection that passes through a break in 
the skin. In a percutaneous system, the acoustic energy is transferred to the bone via the 
abutment, thus it is also an active system. Percutaneous systems are considered the ‘gold 
standard’ of bone conduction devices (Pittman, 2019a). They provide a better signal quality than 
soft-band devices (Pittman, 2019b). An example of an active percutaneous system is the Baha 
Connect System by Cochlear which uses a metal abutment. Oticon also manufactures a device in 
this category. Percutaneous systems carry a small risk of complications including infection, 
failure to osseointegrate, and damage due to trauma (Dun et al., 2012). 
In contrast, a transcutaneous system has no hard connection and the acoustic or digital 
signal passes through the skin while leaving the skin intact. An example of a passive 
transcutaneous system is a soft-band bone conduction device. Another example is the Baha 
Attract System by Cochlear, which uses a magnet to correctly position a transducer above the 
implanted portion, and the acoustic signal is transferred transcutaneous through the skin to the 
implanted portion which is osseointegrated. However, transcutaneous devices are also not 
without drawbacks. These devices require adequate transducer power and a minimum magnetic 
or tension force to adequately transfer acoustic energy from the external transducer to the bone, 
which can sometimes cause inflammation, pain and headaches (Lustig et al., 2001). Further, soft 
tissue attenuation can reduce sound quality (Håkansson et al., 1990). 
The term ‘transcutaneous’ can be used not only in the context of transferring acoustic 
energy but also for digital signals. A common example of a system that transmits a digital signal 
transcutaneously is a modern cochlear implant (CI) that uses a Radio Frequency (RF) link 
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between the inductor coils of the external and internal portions of the CI (Buchegger et al., 2005; 
Zeng, Rebscher, Harrison, Sun, & Feng, 2008). The Bonebridge uses this same principle.  
The Bonebridge System 
Description 
The MED-EL Bonebridge is a “bone conduction implant system” that is indicated for 
CHL, MHL and SSD (MED-EL, n.d.-b). It has the benefit of being able to provide active bone 
conduction whilst being a transcutaneous system that leaves the skin intact. It consists of an 
external and internal portion. The external portion contains microphones and the sound processor 
and is held in place magnetically. The digital signal is transmitted transcutaneously to the implant 
via inductor coils. The internal (implanted) portion, shown in Figure 1, consists of a magnet that 
is used to secure the processor, inductor coil to receive the digital signal, a demodulator which is 
the ‘electronics’ of the internal portion and a bone conduction transducer called the Bone 
Conduction – Floating Mass Transducer (BC-FMT). The BC-FMT is fixed to the bone via two 
screws that are osseointegrated, and is positioned within the mastoid (MED-EL, n.d.-a), see 
Figure 2. 
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Figure 1. Model BC 601 implant. Photo credit: MED-EL (used with permission). 
 
Figure 2. Representation of the Samba processor, BC 601 implant and anatomy.  
Photo credit: MED-EL (used with permission). 
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Clinical Outcomes 
On evaluation of the studies performed thus far, the Bonebridge has been found to 
produce positive audiological outcomes. A study looking at clinical outcomes by Riss et al. 
(2014) found that the Bonebridge produced good functional gain and speech perception in 
recipients that have BC thresholds of 45 dB HL or better. Another study by Wimmer et al. (2019) 
documented that the Bonebridge produced improved thresholds and word recognition results 
compared to unaided measures. Further, they suggest that the indication criteria for the 
Bonebridge device should be persons with BC thresholds of 38 dB HL or better in their better 
ear. Similarly, Weiss et al. (2017), Schmerber et al. (2017), and Skarżyński et al. (2019) 
documented significant improvement in speech perception in quiet and in noise after 
implantation with the Bonebridge. 
Weiss et al. (2017) looked at clinical outcomes and patient acceptance of the Bonebridge. 
They reported that there were no surgical site infections in their study group. Further, using an 
adapted version of the Bern Benefit in Single Sided Deafness questionnaire, they found that 
overall, users reported a high level of acceptance and satisfaction with the Bonebridge. 
Schmerber et al. (2017) also reported good patient satisfaction with the Bonebridge, as well as 
good skin safety. Lassaletta, Calvino, Zernotti, and Gavilán (2016) found that Bonebridge 
implantation does not cause significant pain post-operatively, and the levels of pain are in line 
with other procedures such as CI implantation. 
To date, only one study of the Bonebridge has been conducted in New Zealand 
(Kulasegarah, Burgess, Neeff, & Brown, 2018). These researchers looked at clinical outcomes in 
children with atresia and microtia. It is not fully known if the clinical improvements described 
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above are also seen in a New Zealand adult population. Therefore, the first goal of this study is to 
document clinical outcomes of the Bonebridge device in the New Zealand context. 
Health Related Quality of Life Outcomes 
The World Health Organization defines Quality of Life (QoL) as an “individuals’ 
perceptions of their position in life in the context of the culture and value system in which they 
live and in relation to their goals, expectations, standards and concerns”. This concept is broad in 
its application and includes health, psychological, social and environmental domains (The 
Whoqol Group, 1998). Health Related Quality of Life (HRQoL) is a term with a narrower scope. 
Although there is no single agreed upon definition of HRQoL, in this thesis, it is defined as a 
person’s physical and emotional well-being, their experienced quality of life, as affected by their 
health status (Busija et al., 2011; Karimi & Brazier, 2016).  
There are several self-report tools available in audiology to assess HRQoL for hearing-
related health conditions. Schmerber et al. (2017) used the Abbreviated Profile of Hearing Aid 
Benefit (APHAB; Cox & Alexander, 1995), the Glasgow Benefit Inventory (GBI; Robinson, 
Gatehouse, & Browning, 1996), and the International Outcome Inventory- hearing aids (IOI-HA; 
Cox & Alexander, 2002) questionnaires, where they also documented improvements. Skarżyński 
et al. (2019) also documented improvements via the APHAB following Bonebridge implantation.  
The speech, spatial and qualities of hearing scale (SSQ) is a self-report tool that aims to 
be sensitive to not only the traditionally important speech component of hearing but also to the 
spatial components of hearing such as directionality and movement, as well as the quality 
components of hearing such as naturalness of sound and ability to distinguish multiple sources of 
sound (Gatehouse & Noble, 2004). The SSQ12, is a short form 12-question version that has been 
developed and is shown to produce similar results to the original 49-question SSQ (Noble, 
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Jensen, Naylor, Bhullar, & Akeroyd, 2013). A thesis by Cox (2016) demonstrated that the SSQ12 
has good test-retest reliability.  
Eberhard, Olsen, Miyazaki, Bille, and Caye-Thomasen (2016) used the SSQ12 
questionnaire where they documented good self-reported ability in the quality component 
questions, but relatively poor ability in the sound localization component questions. Laske, 
Röösli, Pfiffner, Veraguth, and Huber (2015) used the SSQ-B (benefit version; Jensen, Akeroyd, 
Noble, & Naylor, 2009) in an SSD only cohort and document the most benefit in the speech 
component questions. They also documented some benefit in the spatial and quality component 
questions.  
Hearing aid usage and frequency is widely considered to be an important outcome 
measure for rehabilitation and is associated with the benefit and satisfaction obtained from using 
a device (Cox & Alexander, 1999; Uriarte, Denzin, Dunstan, Sellars, & Hickson, 2005). In 
addition, a study with hearings aids found that there is a link between a person’s dexterity and 
their ability to effectively use hearing aids (Kumar, Hickey, & Shaw, 2000). Further, hearing aid 
design factors can influence how easy a device is to mount and use (Erber, 2003; Meredith & 
Stephens, 1993). Therefore, it is important to obtain information about device frequency and 
duration of use, as well as ease of use when obtaining HRQoL data. 
The Health Utilities Index (HUI®) is a system to derive single and multi-attribute level 
health utility scores and is a measure of HRQoL (Horsman, Furlong, Feeny, & Torrance, 2003). 
The HUI is a validated system to calculate quality adjusted life years (QALYs) which can then be 
used to evaluate the cost-effectiveness of an intervention (Furlong et al., 2012). Possible scores 
range from -0.36 indicating a state worse than death, to 1 indicating a state of perfect health. It 
appears that HUI data on the Bonebridge has not yet been published. As a point of interest, 
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(Monksfield, Jowett, Reid, & Proops, 2011) used the HUI mark 3 (HUI3), which is sensitive to 
changes in hearing and language, to calculate QALYs and subsequent cost effectiveness for a 
percutaneous bone conduction device. 
Rational 
To date there has been no data collected on the Bonebridge used in adults in NZ. Health 
care systems differ between countries. Therefore, there is a need to obtain data in the NZ context. 
The first aim of this study was to obtain clinical outcome data. The second aim of this study was 
to obtain HRQoL life data. 
Methods 
Power analysis 
The G*Power software program was used to determine the required sample size for this 
study. The alpha-level was set to 0.5 and effect sizes were determined based on previous 
research. The total required number of participants was 20 which was determined by sample size 
analysis. 
Ethics Approval 
This study obtained ethics approval on 2nd May 2019 from the University of Canterbury 
Human Ethics Committee (Appendix A). Further, this study was also deemed by the Health and 
Disability Ethics Committees (HDEC) as being outside the scope of requiring review by HDEC 
(Appendix B). 
Study Design 
When evaluating the outcomes of the Bonebridge, this study used patient reported 
outcome measures to assess HRQoL outcomes, and standard clinical test batteries to assess 
clinical outcomes. This study used one group of participants receiving the Bonebridge as the 
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intervention. The participants served as their own control. Demographic data were collected on 
or before the day of switch-on. Clinical measures were assessed on the day of switch on and at 4 
weeks post switch-on. HRQoL questionnaires were collected in a cross-sectional manner at 6 and 
12 months post switch-on. This design was selected because it provides a comparison of 
outcomes before and after an intervention. The limitation of this design is that it does not allow 
for control of changing factors during the study timeframe (Thiese, 2014). Other interventional 
study design types such as randomized control trials could not be used with this study because all 
participants had elected to receiving the intervention as part of their health care and were to be 
receiving the intervention regardless of participation in the study.  
There was a total of four assessment points:  
T0 – Demographic data collection and consent process prior to switch on 
T1 – clinical assessments at time of switch-on and 4 weeks post switch-on 
T2 – patient reported outcome questionnaires at 6 months 
T3 – patient reported outcome measures at 12 months. 
Participants 
Recruitment was conducted solely at the Christchurch Hospital Ear, Nose and Throat 
(ENT) department. Adults who were receiving medical care by the ENT specialists and had 
elected to undergo Bonebridge implantation, were invited to participate in the study by the ENT 
specialist. 
Participants must have been 18 years of age or older at the time of recruitment, they must 
have elected to undergo the Bonebridge implantation procedure, and they must have been able to 
complete the study questionnaires in the English language. There were no specific exclusion 
criteria for this study. 
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Clinical Outcome Measures 
Audiometric Thresholds 
The objective assessments were completed at an audiology clinic by a New Zealand 
Audiological Society (NZAS) certified audiologist. Testing was conducted in a sound treated 
room calibrated to ISO standards. Audiometric equipment included GSI 61 audiometer, 3M 3a 
insert transducers, the RadioEar B71 bone conductor coupled with a steal tension band, the 
Telephonics TDH-39 transducer and a sound field loud speaker. The room and all audiometric 
equipment were within calibration date.  
Baseline unaided audiometric thresholds were assessed prior to the implantation surgery. 
Ear specific air conduction thresholds were obtained at 500, 1000, 2000, 4000, 6000 and 8000 
Hz. Bone conductions thresholds were obtained at 500, 1000, 2000 and 4000 Hz. In some cases, 
a ‘no response’ was recorded on the audiogram at the level of the limit of the audiometer. In 
those cases, thresholds were entered for data analysis as the limit of the audiometer plus 5 dB. If 
the threshold was below zero, the measured threshold was recorded on the audiogram. In these 
cases, the thresholds were entered for data analysis as 0 dB HL. This was consistent with the 
British Society of Audiology (2011) guidelines. Bone conduction thresholds were obtained at 
500, 1000, 2000, and 4000 Hz.  
Switch-on took place 2 to 4 weeks post-surgery. The Bonebridge was fitted and adjusted 
to subjective preference if required. Unaided and aided audiometric thresholds were assessed in 
the sound-field at 500, 1000, 2000, 4000, and 6000 Hz. The participant was seated with their 
head position above the calibration floor markers with the loudspeaker at 0 degrees azimuth to 
their head. Masking was applied when indicated. 
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Speech Audiometry 
 At T1, speech discrimination scores (SDS) in quiet were assessed using the Arthur 
Boothroyd (1968) consonant-vowel- consonant word list recorded from a male speaker in the NZ 
accent. Participants were mostly tested at three or more intensities to obtain an optimal three-
point performance-intensity (PI) function in accordance with the clinic’s procedural guidelines. 
The intensity level at which participants obtained maximum SDS in the unaided and aided 
condition was compared. This thesis will define maximum SDS as the highest SDS obtained 
under the condition. This is distinct from a true PI maximum (PIMax) because some participants 
were not able to obtain a true PIMax under the sound field conditions due to equipment 
limitations. 
Half peak levels (HPLs), mathematically derived from each participants’ PI function, 
were compared in the aided and unaided conditions. The method for deriving HPL using Excel 
Solver is illustrated in Figure 3. SDS at 50 dB HL (SDS50) in the unaided and unaided 
conditions were compared. If a PI function lacked a data point at 50 dB HL, the SDS50 was 
derived using Excel Solver. 
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Figure 3. Example of Excel Solver function output for participant 2 in the aided condition. The 
midpoint provides HPL readout within Excel. 
Under the same conditions, speech discrimination in noise was assessed using the Quick 
Speech-in-Noise Test (QuickSIN; Killion, Niquette, Gudmundsen, Revit, & Banerjee, 2004) and 
expressed as signal-to-noise ratio (SNR) loss. The same tests were then assessed in the aided 
state, all in the sound field. A mean was taken from two QuickSIN lists for both the unaided and 
aided conditions. 
Health Related Quality of Life Outcome Measures 
Patient reported outcome measures were assessed using pen-and-paper questionnaires 
that were posted to the participants who then completed them, and return posted them to the 
University of Canterbury. Measures used to assess the HRQoL benefits of the Bonebridge were 
the Bone Conduction Device Questionnaire (BCDQ); and the Speech, Spatial, Qualities of 
hearing Questionnaire 12 Benefit version (SSQ12-B; Noble et al., 2013). HRQoL data were also 
collected using the Health Utilities Index questionnaire (Horsman et al., 2003). 
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The BCDQ is an in-house developed questionnaire designed specifically for the 
Bonebridge (Appendix C). It includes five items covering frequency of use, duration of use, ease 
of use, and perceived effect the Bonebridge has on vocational performance. This questionnaire 
was administered at T2 and T3. The SSQ12-B is an abbreviated version of the original SSQ-49. 
It includes 12 scored questions that enabled the participant to compare perceptions before and 
after an intervention (Noble et al., 2013). A modified version of the SSQ12-B was administered 
at T2 and T3. The modification was derived from a previous (unpublished) study’s methodology. 
The response anchors were modified so that “much worse” corresponded to -5 and “much better” 
corresponded to +5 for every item. Instructions were also modified to include the word 
“Bonebridge” to provide clarity for participants who also use AC hearing aids. 
The HUI is a 15-item questionnaire that can be used to derive multiple measures of a 
person’s health state. One measure is the HUI mark 3 (HUI3) health utility score. HUI3 was 
selected because it has been shown to be responsive to the effects of hearing aid intervention 
(Janneke et al., 2007). This questionnaire was administered at 12 months or greater, post switch-
on. Permission was obtained from the publisher to modify the wording of questions to include 
the term “Bonebridge” alongside the term “hearing aids”. The HUI3 was administered at T3 and 
the utility score compared with population normative data 
Analyses 
Descriptive statics were calculated for demographic data. The original intention for this 
study was to complete paired means T-tests for pre and post audiometric and speech 
understanding outcome measures, and for the patient reported outcome measures at T2 and T3. 
Because these data were not normally distributed, Wilcoxon signed ranks tests were used instead. 
The statistical analysis was completed using IBM SPSS version 25 software. The HUI3 utility 
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score was manually calculated using the authors instructions for deriving a multi-attribute level 
score. The scores were compared with population normative data. 
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Results 
Overview 
In this study, it was predicted that Bonebridge recipients would experience improved 
clinical and HRQoL outcomes following implantation. It was also hypothesized that the HRQoL 
outcomes would remain consistent from 6-months through to 12-months post implantation. 
Preliminary analysis of the available data suggests that the Bonebridge provides recipients with 
significantly improved audiometric thresholds and SDS in quiet. Speech discrimination in noise 
improved in a statistically significant way. HRQoL measures generally demonstrated improved 
and consistent HRQoL from 6-months through to 12-months post switch-on. 
Demographics 
This study included 18 participants, nine male and nine female. The age of participants 
ranged from 23 to 74 years with a mean age of 44.56 years. Fifteen participants identified as NZ 
European, two as both NZ European and NZ Māori, and one as NZ. The participants’ level of 
education ranged from early high school level to post-graduate master’s degree. 
Audiometric Thresholds 
The audiometric threshold data were not normally distributed, therefore nonparametric 
analyses were used. See Figure 4 for mean thresholds. A series of Wilcoxon signed ranks tests 
revealed that thresholds were significantly improved in the aided condition when compared with 
the worse ear hearing thresholds for all audiometric frequencies. A Wilcoxon signed Ranks test 
revealed that the aided condition significantly improved thresholds relative to the better hearing 
ear at 4 kHz only. See Table 1 for test statistics and p-values. 
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Table 1 Wilcoxon Signed Ranks Test Statistics and P-Values for the Audiometric Threshold Data. 
Frequency Z (worse ear) P (worse ear) Z (better ear) P (better ear) 
500 Hz -3.625 <.001 -.831 .203 
1 kHz -3.732 <.001 -.527 .299 
2 kHz -3.735 <.001 -.052 .480 
4 kHz -3.685 <.001 -1.945 .026 
6 kHz -3.627 <.001 -1.165 .122 
 
 
Figure 4. Mean aided and unaided thresholds across audiometric frequencies. Bars indicate one 
standard error around the mean. 
Speech Audiometry 
Intensity Level of Maximum Speech Discrimination Score (SDS) 
A Wilcoxon signed ranks test revealed that the intensity level at which participants 
achieved maximum SDS was significantly lower in the aided condition (Median 50) when 
compared to the unaided condition (Median 60) Z = - 3.511, p = < .001. These data are shown in 
Figure 5. Three participants achieved maximum SDS at the same intensity for the unaided and 
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aided conditions. One participant (ID 15) achieved maximum SDS at a higher intensity in the 
aided condition than in the unaided condition. All other participants improved. Change scores 
ranged from -5 to 25 dB HL. Mean change score = 9.44 dB HL (SD = 7.45). 
 
Figure 5. Intensity level at which maximum Speech Discrimination Score (SDS) was achieved 
under the unaided and aided conditions for each participant. 
Half Peak Level (HPL) 
The HPLs were derived mathematically as explained in the methods chapter. This 
technique has limitations that are described in the discussion chapter. A Wilcoxon signed ranks 
test revealed that the intensity of the half peak levels was significantly lower in the aided 
condition (Median = 30.5) compared to the unaided condition (Median = 43.5) Z = - 3.727, p = 
< .001. All participants’ HPL improved. Change scores ranged from 1 to 28 dB HL. Mean 
change score = 13.5 (SD = 8.26). These data are shown in Figure 6. 
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Figure 6. Mathematically derived Half Peak Level (HPL) for each participant. 
Speech Discrimination Score at 50 dB HL (SDS50) 
A Wilcoxon signed ranks test revealed that the sound field SDS score at 50dB HL 
(SDS50) was significantly improved in the aided condition (Median = 97) compared to the 
unaided condition (Median = 71) Z = - 3.409, p = <.001. Three participants had no change. All 
other participants improved. Change scores ranged from 0 to 86%. Mean change score = 31.06% 
(SD = 27.39). These data are shown in Figure 7. 
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Figure 7. Measured and/or derived Speech Discrimination Score (SDS) at 50 dB HL for unaided 
and aided conditions for each participant. 
Speech discrimination in Noise 
The SNR loss as measured by the QuickSIN for each participant is presented in Figure 8. 
No participants scored in the normal range of 0-2 dB. Using 2 dB as the critical change value, 10 
participants experienced an improvement in understanding speech in noise in the aided condition 
relative to the unaided condition and two participants experienced a decrease in performance in 
the aided condition. Seven participants’ scores did not change by 2 dB. A Wilcoxon signed ranks 
test revealed that the overall improvement from the unaided condition (SNR Loss Median = 9.25 
dB) to the aided condition (SNR Loss Median = 6 dB) was significant statically: Z = - 1.966, p 
= .025. Mean change score = 3.47 dB (SD = 6.36). 
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Figure 8. QuickSIN scores expressed as Signal-to-Noise Ratio (SNR) Loss in the unaided and 
aided condition for each participant. 
Health Related Quality of Life 
Of the 18 participants, 15 had completed the T2 (6 month) assessment point, and 14 
completed the T3 (12 month) assessment point at the time of data analysis. While the post 
implant data collection are ongoing, the data collected to date were analyzed for this thesis. 
Those preliminary results are described in the following sections. BCDQ data were available for 
the 15 participants at T2 and for 14 participants at T3. 
Bone Conduction Device Questionnaire 
Usage 
At T2, 11 participants reported using the Bonebridge 7 days a week, two reported using it 
five days and two reported using it four days. Seven participants reported using the Bonebridge 
for 12-16 hours per day; one participant for 8-12 hours; three for 4-8 hours; two for 2-4 hours, 
and; one participant for more than 16 hours per day. Thirteen participants exclusively use the 
Bonebridge. Two participants use the Bonebridge along with another type of hearing aid.  
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Participants reported using the Bonebridge a median of 7 days a week at both T2 and T3 
(Z = .000, p = 1.000). At T3, the median hours of Bonebridge use per day corresponded to 12-16 
hours per day. A Wilcoxon signed ranks test revealed this did not differ significantly from T2 (Z 
= -1.000, p = .317).  
Ease of use 
Figures 9 and 10 illustrate the ease of use data for the study participants. At both 6-
months and 12-months post switch-on, all participants reported the Bonebridge was easy or very 
easy to mount. Similarly, most participants reported that changing the volume and the batteries 
was easy or very easy. A Wilcoxon signed ranks test revealed participant responses were not 
significantly different at T2 and T3 (Z = -1.000, p = .317). 
 
Figure 9. Bone Conduction Device Questionnaire (BCDQ) ease of use question responses at 6 
months (T2). 
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Figure 10. Bone Conduction Device Questionnaire (BCDQ) ease of use question responses at 12 
months (T3). 
Vocational performance 
Participants had the option to mark the vocational performance questions as non-
applicable. These data are shown in Figures 11 and 12. Of the 15 participants who completed the 
questionnaire at 6-months, 12 participants responded to the vocational performance questions. 
Most of the participants (N = 9, 75%) reported that they either strongly agree or agree that the 
Bonebridge causes them to perform better at work. Most participants (N = 8, 66.7%) either 
strongly agreed or agreed that the Bonebridge causes them to be more productive. Half of the 
participants (N = 6, 50%) either strongly agreed or agreed that the Bonebridge causes them to 
miss fewer days at work. Most participants (N = 9, 75%) either strongly agreed or agreed that the 
Bonebridge causes them to have less stress at work. Half of the participants (N = 6, 50%) either 
strongly agree or agree that the Bonebridge causes them to be less tired at work. A Wilcoxon 
signed ranks test revealed that there were no significant changes in perceived vocational 
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performance at 12 months compared with 6 months post switch-on. See Table 2 for statistics and 
P-values. 
Table 2 Wilcoxon Signed Ranks Test Statistics and P-Values for Bone Conduction Device 
Questionnaire (BCDQ) Vocational Questions. 
Question Z P 
Performance -1.342 .180 
Productivity -.447 .655 
Missed days .000 1.000 
Stress -.447 .655 
Tiredness -1.414 .157 
 
 
Figure 11. Bone Conduction Device Questionnaire (BCDQ) vocational performance question 
responses at 6 months (T2). 
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Figure 12. Bone Conduction Device Questionnaire (BCDQ) vocational performance question 
responses at 12 months (T3). 
SSQ12-B 
The SSQ12-B was completed by 15 participants at 6 months and by 14 participants at 12 
months. However, one participant incorrectly filled out the questionnaire at the 12-month 
assessment point and that participant’s data were removed from the analyses. Subsequently there 
are data for only 13 participants at the 12-month assessment point. The data were not normally 
distributed, and a non-parametric approach was used to test the study hypotheses. 
Figures 13, 14 and 15 show the SSQ-B at 6-months and 12-months post switch-on. The 
data indicate benefit (positive scores) following Bonebridge implantation. A Wilcoxon signed 
ranks test revealed no significant change in benefit from the 6-month to the 12-month assessment 
(Z = -1.569, p = .117). This pattern of benefit was seen for all SSQ12-B items with exception of 
item 8 (ability to detect whether a source of a sound is getting closer or further away). For this 
item, participants benefit decreased significantly from 6- to 12-months post-implantation (Z = -
2.393, p = .017) 
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Figure 13. 6-month Speech, Spatial and Qualities of Hearing (SSQ)12-B mean score by item. 
Bars indicate 1 standard error around the mean.  
Note: For figures 13 and 14, the question subscales are as follows: Speech in noise – item 1, 3, 
and 4; Multiple speech streams – item 2 and 5; Localization – item 6; Distance and movement – 
item 7 and 8; Segregation – item 9; Identification of sound – item 10; Quality and naturalness – 
item 11; and, Listening effort – item 12. 
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Figure 14. 12-month Speech, Spatial and Qualities of Hearing (SSQ)12-B mean scores by item. 
Bars indicate 1 standard error around the mean. 
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Figure 15. Total Speech, Spatial and Qualities of Hearing (SSQ)12-B scores at 6 and 12 months 
compared. Bars indicate 1 standard error around the mean. 
Health Utilities Index Mark 3 (HUI3) 
Six participants completed the HUI questionnaire at around 12 months post switch-on. 
These data were used to derive HUI3 utility scores. These data are shown in Table 3. The data 
indicate that some participants have higher utility scores than the control population, while others 
have lower utility scores. 
Table 3 Health Utility Index Mark 3 (HUI3) utility and control scores for study participants 
Participant ID Utility Score Control 
2 .42 .77 
4 .67 .89 
7 .85 .85 
10 .78 .72 
11 .40 .85 
18 .79 .85 
Note: Control data from 2006 Australian population summary statistics, age matched. 
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Discussion  
Overview 
The Bonebridge is a relatively new device that overcomes some of the limitations 
associated with conventional bone conduction devices. Previous studies show positive objective 
and subject outcomes. A systematic review by Magele, Schoerg, Stanek, Gradl, and Georg 
Mathias (2019) looking at 39 studies reported positive objective and subjective outcomes 
following Bonebridge implantation. The aim of this study was to determine to what extent the 
Bonebridge improves clinical and HRQoL outcomes in the NZ context through audiological 
assessments and patient reported outcome measures. The preliminary results suggest that the 
Bonebridge improved clinical outcomes in participants, and that participants perceived an 
improvement in HRQoL at 6 and 12 months post switch-on. 
Audiometric Thresholds 
The aim of this assessment was to determine if the Bonebridge provided participants with 
improved audiometric thresholds. The preliminary results of this study suggest that the 
Bonebridge does provide participants with improved audiometric thresholds, particularly when 
comparing aided thresholds with the worse ear thresholds. This means that participants have 
improved access to sound across tested frequencies. The mean threshold data (Figure 4) is taken 
from all participants of which have a range of hearing loss configurations. Within the sample 
there are participants with bilateral CHL, unilateral CHL, MHL and SSD. The Bonebridge was 
implanted on the side of the worse ear. Therefore, the finding that aided thresholds are not 
significantly better than unaided better ear thresholds at all frequencies was expected. In other 
words, it was expected that less improvement would be measured in the aided state if the person 
had normal hearing in their better ear. The protocols of this study were developed during the 
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early stages of Bonebridge research. One other study by Rahne et al. (2015) used ear specific 
thresholds prior to surgery and compared them to aided sound field thresholds. They reported 
significant improvements. Most other Bonebridge literature used unaided and aided sound field 
thresholds after surgery to measure functional hearing gain. They measured significant 
improvement in audiometric thresholds for the Bonebridge (Ngui & Tang, 2018; Oh et al., 2019; 
Riss et al., 2014; Schmerber et al., 2017; Skarżyński et al., 2019; Weiss et al., 2017). 
Speech Discrimination 
The aim of these assessments was to determine if the Bonebridge provided participants 
with improved speech discrimination in quiet. The preliminary results of these assessments 
suggest that it does. 
Level of Maximum SDS 
The preliminary results indicate that no participant’s level decreased significantly, and 
most experienced improvement in the level at which they were able to obtain the maximum SDS 
with the AB word list. This provides evidence of an improvement in the audibility of speech. 
This finding is in line with Schmerber et al. (2017) who reported improved change scores of 16 
to 19 dB. The exceptions to this were participants 14, 15, 17 and 18 where the difference in 
intensities for the unaided and aided maximum SDS were not clinically significant. The reasons 
for this occurring in participants 14 and 15 are not known. Participants 17 and 18 likely did not 
realize improvement because both had SSD indications. 
Half Peak Level 
The key finding of the preliminary results was that all participants’ HPL improved in the 
aided condition. This provides further indication that in a clinical environment, all participants 
had improved audibility of speech. For some participants, audibility was minimally improved 
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while for other participants, audibility was greatly improved. A search of the relevant literature 
indicated that using HPLs to compare audiological outcomes in the unaided and aided conditions 
has not been used in previous studies.  
SDS50 
The key finding for this measurement was that participants’ SDS at 50 dB HL, a quiet 
conversation level, was significantly improved in the aided condition. This indicates that most 
participants experienced an improved understanding of speech at this level. Some participants 
experienced the ceiling effect. No participants’ understanding decreased. This outcome is 
consistent with other studies who also measured improved speech discrimination at set intensity 
levels (Eberhard et al., 2016; Gerdes, Salcher, Schwab, Lenarz, & Maier, 2016; Oh et al., 2019; 
Rahne et al., 2015; Riss et al., 2014; Schmerber et al., 2017; Skarżyński et al., 2019; Weiss et al., 
2017). It must be noted that each of the above-mentioned studies either used different intensities 
or measured it in Sound Pressure Level.  
SNR Loss 
The QuickSIN measurement produced variation in scores unaided and aided as well as in 
the change scores. Most participants’ scores did improve, indicating improved ability to 
understand speech in noise. It is worth noting that some participants experienced no critical 
change and two had poorer scores in aided condition. The overall improvement in ability to 
understand speech in noise is generally consistent with other studies. However, other studies 
found stronger results. 
A thorough search of relevant literature revealed that this was the only other study to use 
QuickSIN for measuring Bonebridge outcomes. Kulasegarah et al. (2018) measured a significant 
improvement in SNR Loss among four participants from an unaided range of 3.7-10.5 to aided 
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0.2-1.2 SNR Loss using an unspecified combination of the QuickSIN and Bench-Kowal-
Bamford (BKB; Bench, Kowal, & Bamford, 1979) speech in noise test. Other studies commonly 
used mono or disyllabic word lists with noise presented simultaneously to obtain a word score or 
SRT measured as Db SNR. Skarżyński et al. (2019) reported improved SRTs in noise from 
median 12.8 dB SNR to median -1.1 dB SNR using a Polish Sentence test with noise presented 
at 0 degrees azimuth. Weiss et al. (2017) also reported improved SRTs from -3.8 dB SNR to -5.2 
dB SNR. Schmerber et al. (2017) reported significant improvement in scores from an average 
62% to 89% using the French language dissyllabic words (Fournier, 1951) with noise presented 
simultaneously at 180 degrees azimuth. Ihler, Volbers, Blum, Matthias, and Canis (2014) 
reported improved speech scores from average 8.3% to 37.5% using the German language 
Freiburg Monosyllabic Test (Hahlbrock, 1953) with speech weighted noise presented 
simultaneously. Oh et al. (2019) also measured a significant improvement in scores measured 
with a Korean monosyllabic word list with noise presented simultaneously at 0 degrees azimuth. 
Finally, Rahne et al. (2015) report significantly improved SNR measured using the SRT of 
sentences in noise. A possible reason for the current studies SNR Loss results not being as strong 
as those of other studies may be because SNR Loss was tested 1-month post switch on. A longer 
time frame may allow for more thorough acclimatization and potentially improve SNR Loss 
outcomes to a greater extent. 
Bone Conduction Device Questionnaire 
The aim of administering the BCDQ was to obtain self-reported information on 
frequency and duration of usage, perception of ease of use, and perception of vocational 
performance improvements obtained through use of the Bonebridge. Most participants reported 
using the Bonebridge 7 days a week for 12-16 hours/day. This is a reasonable indication that 
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participants liked the device and perceived benefit in using it. These results are consistent with 
Schmerber et al. (2017) who reported that 11 out of 12 participants used their Bonebridge for the 
whole day as measured using the IOI-HA. This and the current studies reported amount of 
frequency and duration of usage is higher than found by Eberhard et al. (2016) who, using their 
own frequency and duration questionnaire, reported an average use of 5.5 days/week with 50% 
of participants using the device for 8 hours or more per day.  
This study also sought to obtain information on ease of use and vocational outcomes with 
the Bonebridge. Almost all participants reported that the Bonebridge is easy to use in terms of 
correct mounting, changing volume and changing batteries. Further, participants perceived that 
the Bonebridge did improve vocational performance. A thorough search of the relevant literature 
revealed that no other study has assessed self-reported vocational outcome data with the 
Bonebridge. It must also be noted that the BCDQ was developed in-house therefore the findings 
are not directly comparable to other studies. 
SSQ12-B 
The key finding of this outcome measure was that, overall, participants reported that the 
Bonebridge provided benefit in speech, spatial and qualities of hearing. This translates to an 
improved ability to understand speech in the presence of competing noise, receive multiple 
sources of speech, and to correctly localize sounds (Gatehouse & Noble, 2004). A literature 
search revealed that the SSQ12-B (short form) has likely not been used in any studies with the 
Bonebridge. However, one study by Laske et al. (2015) measured outcomes with the SSQ-B (full 
version) on nine participants with SSD. Overall, their participants found good benefit in the 
speech domain, and some benefit in the spatial and quality domains. Because the SSQ-B 
correlates with the SSQ12-B (Noble et al., 2013), it can be inferred that the current study 
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achieved stronger results in the spatial and quality domains than those of Laske et al. (2015). 
This is likely a reflection of the current study’s larger sample size and make-up of predominantly 
CHL and MHL. 
Health Utilities Index 
The HUI function is derived from multiple health attribute level scores. Therefore, scores 
that are lower than control should not be solely attributed to Bonebridge implantation. Further, 
the small sample size of the current study does not allow a conclusion to be made. Future studies 
should obtain before and after HUI function scores to obtain HRQoL data that is more sensitive 
to Bonebridge implantation. Such data could be used to calculate the cost effectiveness of the 
Bonebridge. A literature search revealed that no other study has yet obtained HUI3 utility data 
but a study by Vickers et al. (2018) plans to use HUI2 and 3 to obtain data with the Bonebridge. 
SSD Indication 
Included in the results are data from two SSD participants indicated by the asterisk in the 
figures in the results chapter. These participants belong to a different clinical subpopulation 
whose condition can also be managed with the Bonebridge. Persons with SSD lack binaural 
input, resulting in reduced sound localization and SNR performance (Agterberg, Hol, Van 
Wanrooij, Van Opstal, & Snik, 2014; Harford & Dodds, 1966). Management options normally 
aim to eliminate or reduce the head shadow effect (Harford & Dodds, 1966; Hol et al., 2010). 
However, the audiological outcomes measured in the current study did not specifically assess for 
benefit to SSD participants. This is likely the reason that SSD participants did not experience 
significant improvement in audiological outcomes. However, SSD participants generally 
reported improved HRQoL outcomes. 
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Other studies have incorporated directionality when testing speech discrimination in 
noise with the Bonebridge. Salcher, Zimmermann, Giere, Lenarz, and Maier (2017) reported 
significant improvement in all tested directional scenarios. Laske et al. (2015) and Schmerber et 
al. (2017) reported statistically significant improvements when the signal was presented on the 
side of the Bonebridge.  
Indeed, CIs remain the only possibility to restore binaural hearing effect in persons with 
SSD (Agterberg et al., 2014). CIs and implantable bone conduction devices both incur surgery 
related costs. Therefore, cost-effectiveness analysis should inform future decisions when 
considering management options for SSD. 
Limitations and Future Research 
The study has limitations that are inherent to field research. Clinical outcome data was 
collected in a clinical environment by multiple clinicians. Further, patient reported outcome 
measures were completed by participants in their natural environment using pen and paper. This 
contrasts with research conducted in a lab were the research is main effort and the researchers 
can more closely control test conditions to achieve consistency 
Mathematically deriving HPLs carries the limitation that an assumption must be made as 
to whether each participant is able to attain a PIMax of 100%. Further, a limitation associated 
with the audiometric thresholds is that unaided thresholds were measured prior to surgery using 
ear specific transducers, while aided thresholds were measured on the day of switch-on in the 
sound field. This method does not account for possible deterioration in hearing loss as a result of 
surgery, or the for the potential differences as a result of binaural summation that may be present 
in the aided condition. Comparison is therefore not direct. This study attempted to mitigate this 
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limitation by including half peak level measurements which are commonly used to cross-check 
audiometric thresholds.  
It is suggested that future studies measure unaided ear specific PTA both before and after 
surgery to determine if a hearing loss had deteriorated since the time of surgery. It is also 
suggested that future studies measure both unaided and aided sound field thresholds at the same 
assessment point post switch-on. 
Conclusions 
The aim of these assessments were to determine to what extent the Bonebridge improves 
clinical and HRQoL outcomes in the NZ context. The key findings were that the Bonebridge 
provided participants with significant benefit in both clinical and HRQoL outcomes. Benefit was 
not measured to be as strong with speech discrimination in noise. Future studies will be needed 
to verify the true degree of benefit in comparison to other interventions. 
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have submitted, it does not appear to be within the scope of HDEC review. This scope is 
described in section three of the Standard Operating Procedures for Health and Disability 
Ethics Committees. 
 
This study involves participants who meet the criteria for Bonebridge implantation and will 
assess their quality of life before and after implantation. This is not an intervention study 
and the implantation of this device will not be in any way controlled or determined by 
participation in this study. These participants will be recruited by their surgeon who will be 
informed of the research and will not be accessing participants’ health information for the 
purpose of recruitment. Participants are not considered vulnerable and will provide 
informed consent to participate in this study before their health information is accessed 
and will not have any tissue used or collected. 
 
An observational study requires HDEC review only if the study involves more than 
minimal risk (that is, potential participants could reasonably be expected to regard the 
probability and magnitude of possible harms resulting from their participation in the study 
to be greater than those encountered in those aspects of their everyday life that relate to 
the study). 
 
For the avoidance of doubt, an observational study always involves more than minimal 
risk if it involves one or more of the following: 
x one or more participants who will not have given informed consent to participate, 
or 
x one or more participants who are vulnerable (that is, who have restricted 
capability to make independent decisions about their participation in the study), or 
x standard treatment being withheld from one or more participants, or 
x the storage, preservation or use of human tissue without consent, or 
x the disclosure of health information without authorisation. 
 
If you consider that our advice on your project being out of scope is in incorrect please 
contact us as soon as possible giving reasons for this. 
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This letter does not constitute ethical approval or endorsement for the activity described 
in your application, but may be used as evidence that HDEC review is not required for it. 
 
Please note, your locality may have additional ethical review policies, please check with 
your locality. If your study involves a DHB, you must contact the DHB’s research office 
before you begin. If your study involves a university or polytechnic, you must contact its 
institutional ethics committee before you begin. 
 












Bone Conduction Device Questionnaire (BCDQ)   Date: _________________  
 
Please answer each question to the best of your ability 
 
1. Around how many days a week do you use your Bonebridge? (please tick one box) 
F  I do not use it (0)  F  4 days 
F 1 day    F 5 days 
F 2 days    F 6 days 
F 3 days    F 7 days 
 
2. Around how many hours each day do you use your Bonebridge? (please tick one box) 
F I do not use it (0)  F 8 – 12 hours 
F Less than 2 hours  F 12 – 16 hours 
F 2 – 4 hours   F More than 16 hours 
F 4 – 8 hours   F I don’t know 
 
3. Do you use any other type of hearing aid?    F Yes F  No 
 
If yes, what type of aid do you use? _________________________________ 
 
4. How well can you care for your Bonebridge (please tick one box for each task)? 





     
Changing 
volume 
     
Changing 
batteries 
     
 
5. How has the Bonebridge affected your work  (please tick one box for each line)? If you do 
not work, please leve this table blank.  
 Strongly 
Agree 
Agree Not Sure Disagree Strongly 
Disagree 
I perform better      
I am more 
productive 
     
I miss fewer days      
I have less stress      
I am less tired      
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